Ariad Pharmaceuticals-Neu

ARIAD Pharmaceuticals, Inc. at the Morgan Stanley Global Healthcare Conference

Monday, September 12, 2016 2:50 p.m. ET

 

http://phx.corporate-ir.net/...NoaWxkSUQ9MzUxNTA3fFR5cGU9MQ==&t=1  

09/12/16 SC 13G/A An amendment to the SC 13G filing

http://investor.ariad.com/...x.zhtml?c=118422&p=irol-sec#14577317  

kannst du mir bitte den Inhalt auf deutsch geben. Ich beherrsche die englishe sprache nicht so gut
 

Na das wird wohl jetzt werden :-)
Im After Markt stark angezogen
Momentan bei
10.79$  

Produkt wird hier über eine Zulassung erwartet
 

New Drug Application for Brigatinib to the U.S. Food and Drug Administration

http://investor.ariad.com/...p=RssLanding&cat=news&id=2198158  

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced several data presentations on Iclusig (ponatinib) that will take place at the 18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy being held in Houston, September 15 to 18, 2016. A total of eight abstracts will be presented, including two oral presentations. The schedule and abstract information are listed below:



Oral Presentations


Title:  
Long-term Efficacy and Safety of Ponatinib in Heavily Pretreated Leukemia Patients: 4-Year Results from the Pivotal Phase 2 PACE Trial

Oral Session:   Scientific Session 7: Therapeutic Interventions
Date & Time:   Saturday, September 17, 2016, 4:25-5:45 p.m. CT, Presentation at
  5:00 p.m. CT
Presenter:   Jorge E. Cortes, M.D., (The University of Texas MD Anderson Cancer Center)
   
Title:  
Impact of Early Responses on 3-Year Outcomes in Heavily Pretreated CP-CML Patients: Landmark Analyses in the Pivotal Ponatinib PACE Trial

Oral Session:   Scientific Session 8: Predictors and Modeling Response
Date & Time:   Sunday, September 18, 2016, 8:30-10:05 a.m. CT, Presentation at
  8:50 a.m. CT
Presenter:   Martin C. Müller, M.D. (Universitätsmedizin Mannheim, Mannheim)
 



Ponatinib Posters
   
   
Title:  
A Superiority Trial of Two Lower Doses of Ponatinib Versus Standard Dose Nilotinib in Second-Line Chronic Phase CML, the OPTIC-2L Trial

Poster Session:   Trials in Progress
Date:   Thursday, September 15, 2016
   
Title:  
A Evaluation of Three Doses of Ponatinib in a Multicenter, Randomized Phase 2 Trial with Response-Based Dose Reduction, the OPTIC Study

Poster Session:   Trials in Progress
Date:   Thursday, September 15, 2016
   
Title:  
Ponatinib Therapy for Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Patients: Real-world Clinical Practice Versus the PACE Trial

Poster Session:   Clinical Poster
Date:   Thursday, September 15, 2016
   
Title:  
Ponatinib Versus Bosutinib in 3rd-Line Chronic Phase-Chronic Myeloid Leukemia: Indirect Comparison of Efficacy Using Iterative Proportional Fitting

Poster Session:   Clinical Poster
Date:   Thursday, September 15, 2016
   
Title:  
Preliminary Findings from a Chart Review of Lower Dosing of Ponatinib in Chronic Myeloid Leukemia (CML) Patients

Poster Session:   Clinical Poster
Date:   Thursday, September 15, 2016
   
Title:  
The PACE Clinical Trial vs. the Real-world: Comparison of Ponatinib Prescribing and Duration of Therapy in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients

Poster Session:   Clinical Poster
Date:   Thursday, September 15, 2016
   

About Iclusig® (ponatinib) tabletsIclusig is a kinase inhibitor. The primary target for Iclusig is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Iclusig was designed using ARIAD's computational and structure-based drug-design platform specifically to inhibit the activity of BCR-ABL. Iclusig targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, which has been associated with resistance to other approved TKIs. Iclusig is approved in the U.S., EU, Australia, Switzerland, Israel and Canada. In the U.S., Iclusig is a kinase inhibitor indicated for the:
Treatment of adult patients with T315I-positive chronic myeloid leukemia (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated.

These indications are based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Iclusig.

Limitations of use: Iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase CML.

IMPORTANT SAFETY INFORMATION, INCLUDING THE BOXED WARNINGWARNING: VASCULAR OCCLUSION, HEART FAILURE, and HEPATOTOXICITY

See full prescribing information for complete boxed warning
Vascular Occlusion: Arterial and venous thrombosis and occlusions have occurred in at least 27% of Iclusig treated patients, including fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients less than 50 years old, experienced these events. Monitor for evidence of thromboembolism and vascular occlusion. Interrupt or stop Iclusig immediately for vascular occlusion. A benefit risk consideration should guide a decision to restart Iclusig therapy.
Heart Failure, including fatalities, occurred in 8% of Iclusig-treated patients. Monitor cardiac function. Interrupt or stop Iclusig for new or worsening heart failure.
Hepatotoxicity, liver failure and death have occurred in Iclusig-treated patients. Monitor hepatic function. Interrupt Iclusig if hepatotoxicity is suspected.

Vascular Occlusion: Arterial and venous thrombosis and occlusions, including fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures have occurred in at least 27% of Iclusig-treated patients from the phase 1 and phase 2 trials. Iclusig can also cause recurrent or multi-site vascular occlusion. Overall, 20% of Iclusig-treated patients experienced an arterial occlusion and thrombosis event of any grade. Fatal and life-threatening vascular occlusion has occurred within 2 weeks of starting Iclusig treatment and in patients treated with average daily dose intensities as low as 15 mg per day. The median time to onset of the first vascular occlusion event was 5 months. Patients with and without cardiovascular risk factors have experienced vascular occlusion although these events were more frequent with increasing age and in patients with prior history of ischemia, hypertension, diabetes, or hyperlipidemia. Interrupt or stop Iclusig immediately in patients who develop vascular occlusion events.

Heart Failure: Fatal and serious heart failure or left ventricular dysfunction occurred in 5% of Iclusig treated patients (22/449). Eight percent of patients (35/449) experienced any grade of heart failure or left ventricular dysfunction. Monitor patients for signs or symptoms consistent with heart failure and treat as clinically indicated, including interruption of Iclusig. Consider discontinuation of Iclusig in patients who develop serious heart failure.

Hepatotoxicity: Iclusig can cause hepatotoxicity, including liver failure and death. Fulminant hepatic failure leading to death occurred in an Iclusig-treated patient within one week of starting Iclusig. Two additional fatal cases of acute liver failure also occurred. The fatal cases occurred in patients with blast phase CML (BP-CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Severe hepatotoxicity occurred in all disease cohorts. Iclusig treatment may result in elevation in ALT, AST, or both. Monitor liver function tests at baseline, then at least monthly or as clinically indicated. Interrupt, reduce or discontinue Iclusig as clinically indicated.

Hypertension: Treatment-emergent hypertension (defined as systolic BP≥140 mm Hg or diastolic BP≥90 mm Hg on at least one occasion) occurred in 67% of patients (300/449). Eight patients treated with Iclusig (2%) experienced treatment-emergent symptomatic hypertension as a serious adverse reaction, including one patient (<1%) with hypertensive crisis. Patients may require urgent clinical intervention for hypertension associated with confusion, headache, chest pain, or shortness of breath. In 131 patients with Stage 1 hypertension at baseline, 61% (80/131) developed Stage 2 hypertension. Monitor and manage blood pressure elevations during Iclusig use and treat hypertension to normalize blood pressure. Interrupt, dose reduce, or stop Iclusig if hypertension is not medically controlled. In the event of significant worsening, labile or treatment-resistant hypertension, interrupt treatment and consider evaluating for renal artery stenosis.

Pancreatitis: Clinical pancreatitis occurred in 6% (28/449) of patients (5% Grade 3) treated with Iclusig. Pancreatitis resulted in discontinuation or treatment interruption in 6% of patients (25/449). The incidence of treatment-emergent lipase elevation was 41%. Check serum lipase every 2 weeks for the first 2 months and then monthly thereafter or as clinically indicated. Consider additional serum lipase monitoring in patients with a history of pancreatitis or alcohol abuse. Dose interruption or reduction may be required. In cases where lipase elevations are accompanied by abdominal symptoms, interrupt treatment with Iclusig and evaluate patients for pancreatitis. Do not consider restarting Iclusig until patients have complete resolution of symptoms and lipase levels are less than 1.5 x ULN.

Increased Toxicity in Newly Diagnosed Chronic Phase CML: In a prospective randomized clinical trial in the first line treatment of newly diagnosed patients with chronic phase (CP) CML, single agent Iclusig 45 mg once-daily increased the risk of serious adverse reactions 2-fold compared to singe agent imatinib 400 mg once-daily. The median exposure to treatment was less than 6 months. The trial was halted for safety in October 2013. Arterial and venous thrombosis and occlusions occurred at least twice as frequently in the Iclusig arm compared to the imatinib arm. Compared to imatinib-treated patients, Iclusig-treated patients exhibited a greater incidence of myelosuppression, pancreatitis, hepatotoxicity, cardiac failure, hypertension and skin and subcutaneous tissue disorders. Iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed CP CML.

Neuropathy: Peripheral and cranial neuropathy have occurred in Iclusig-treated patients. Overall, 13% (59/449) of Iclusig-treated patients experienced a peripheral neuropathy event of any grade (2%, grade 3/4). In clinical trials, the most common peripheral neuropathies reported were peripheral neuropathy (4%, 18/449), paresthesia (4%, 17/449), hypoesthesia (2%, 11/449), and hyperesthesia (1%, 5/449). Cranial neuropathy developed in 1% (6/449) of Iclusig-treated patients (<1% grade 3/4). Of the patients who developed neuropathy, 31% (20/65) developed neuropathy during the first month of treatment. Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain or weakness. Consider interrupting Iclusig and evaluate if neuropathy is suspected.

Ocular Toxicity: Serious ocular toxicities leading to blindness or blurred vision have occurred in Iclusig-treated patients. Retinal toxicities including macular edema, retinal vein occlusion, and retinal hemorrhage occurred in 3% of Iclusig-treated patients. Conjunctival or corneal irritation, dry eye, or eye pain occurred in 13% of patients. Visual blurring occurred in 6% of the patients. Other ocular toxicities include cataracts, glaucoma, iritis, iridocyclitis, and ulcerative keratitis. Conduct comprehensive eye exams at baseline and periodically during treatment.

Hemorrhage: Serious bleeding events, including fatalities, occurred in 5% (22/449) of patients treated with Iclusig. Hemorrhagic events occurred in 24% of patients. The incidence of serious bleeding events was higher in patients with accelerated phase CML (AP-CML), BP-CML, and Ph+ ALL. Most hemorrhagic events, but not all occurred in patients with grade 4 thrombocytopenia. Interrupt Iclusig for serious or severe hemorrhage and evaluate.

Fluid Retention: Serious fluid retention events occurred in 3% (13/449) of patients treated with Iclusig. One instance of brain edema was fatal. In total, fluid retention occurred in 23% of the patients. The most common fluid retention events were peripheral edema (16%), pleural effusion (7%), and pericardial effusion (3%). Monitor patients for fluid retention and manage patients as clinically indicated. Interrupt, reduce, or discontinue Iclusig as clinically indicated.

Cardiac Arrhythmias: Symptomatic bradyarrhythmias that led to a requirement for pacemaker implantation occurred in 1% (3/449) of Iclusig-treated patients. Advise patients to report signs and symptoms suggestive of slow heart rate (fainting, dizziness, or chest pain). Supraventricular tachyarrhythmias occurred in 5% (25/449) of Iclusig-treated patients. Atrial fibrillation was the most common supraventricular tachyarrhythmia and occurred in 20 patients. For 13 patients, the event led to hospitalization. Advise patients to report signs and symptoms of rapid heart rate (palpitations, dizziness). Interrupt Iclusig and evaluate.

Myelosuppression: Severe (grade 3 or 4) myelosuppression occurred in 48% (215/449) of patients treated with Iclusig. The incidence of these events was greater in patients with AP-CML, BP-CML and Ph+ ALL than in patients with CP-CML. Obtain complete blood counts every 2 weeks for the first 3 months and then monthly or as clinically indicated, and adjust the dose as recommended.

Tumor Lysis Syndrome: Two patients (<1%) with advanced disease (AP-CML, BP-CML, or Ph+ ALL) treated with Iclusig developed serious tumor lysis syndrome. Hyperuricemia occurred in 7% (30/449) of patients overall; the majority had CP-CML (19 patients). Due to the potential for tumor lysis syndrome in patients with advanced disease, ensure adequate hydration and treat high uric acid levels prior to initiating therapy with Iclusig.

Compromised Wound Healing and Gastrointestinal Perforation: Since Iclusig may compromise wound healing, interrupt Iclusig for at least 1 week prior to major surgery. Serious gastrointestinal perforation (fistula) occurred in one patient 38 days post-cholecystectomy.

Embryo-Fetal Toxicity: Iclusig can cause fetal harm. If Iclusig is used during pregnancy, or if the patient becomes pregnant while taking Iclusig, the patient should be apprised of the potential hazard to the fetus. Advise women to avoid pregnancy while taking Iclusig.

Most common non-hematologic adverse reactions: (≥20%) were hypertension, rash, abdominal pain, fatigue, headache, dry skin, constipation, arthralgia, nausea, and pyrexia. Hematologic adverse reactions included thrombocytopenia, anemia, neutropenia, lymphopenia, and leukopenia.

Please see the full U.S. Prescribing Information for Iclusig, including the Boxed Warning.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!


You May Also Be Interested In
ARIAD Pharma (ARIA) September volatility elevated
Aeglea BioTherapeutics (AGLE) Initiates Dosing in Phase 1 Trial of AEB1102
MasterCraft (MCFT) Prices 4M Common Stock Follow-on Offering at $10.25/Share


 






 

by Taboola

Sponsored Links


You May Like  

dynamische Aufwärtsbewegung jetzt! :-)  

http://www.ariva.de/forum/...euticals-neu-493216?page=120#jumppos3001  

...in den letzten Wochen fas 50%

Bin in Versuchung mal meine Gewinne mitzunehmen, oder wie seht ihr das?
Was denkt ihr wie weit es noch up geht heuer?  

Der Zug in die Berge ist gestartet,
das lange Tal ist jetzt durchwandert.
Ich freu mich auf der Reise zu den 23-24$ dabei zu sein.  
 

nur was ich gemerkt habe ist, dass der Masterbroker eventuell recht hat mit seiner Übernahme aussage. Ich habe extra seine Beiträge nach gelesen er hatte zu größte teils recht gehabt mit seiner vorherigen aussagen......... der typ ist der Hammer.............
 

wenn der Kurs die Tage leicht korrigiert.

                                        §
                              §  

wieso sollen wir unser Finger weg lassen..... wie hoch kann es noch gehen...........was meinst du...  

Hängt von deinem Anlagehorizont ab.

Aber alles unter 20 $ wäre verschenktes Geld.  

dann bleibe ich noch drine.........  

Gewinn!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

 

kommt nach meiner Vermutung eine Übernahme ansonsten kann ich mir nicht vorstellen wieso es jetzt der hohe kurs anstieg kommt
 

...dürfte ja hoffentlich bald erfolgen! Kann gut sein, dass mit der Zulassung auch ein Angebot kommt. ;-)  

über A. Denner ein.

https://en.wikipedia.org/wiki/ARIAD_Pharmaceuticals

On February 21, 2014 Ariad Pharmaceuticals announced the appointment of Sarissa Capital's Alexander J. Denner, Ph.D. to a two-year term on the Company's Board of Directors. Previously, Dr. Denner served as a senior managing director at Carl Icahn's Icahn Capital and is currently Ariad's second-largest shareholder. On January 10, 2016, Ariad announced that Denner had become the chairman of the board, replacing Harvey Berger.[8] Shortly thereafter, the company announced the termination of its shareholder's rights plan (the "poison pill.")[9]  

http://finance.yahoo.com/m/...3d/ss_ariad-pharmaceuticals-(aria).html

Ariad Pharmaceuticals (ARIA) Stock Climbs, Coverage Initiated at Leerink
[TheStreet.com]
Rachel Aldrich
September 26, 2016  

 

Lohnt es sich nachzukaufen wenn es bis auf 20$ springt.  

nur ob es dann noch die "großen" Gewinne bringt.